Larimar Therapeutics, Inc. (LRMR) Stock Grade

About Larimar Therapeutics, Inc.'s fundamentals

Larimar Therapeutics is a biotechnology company with a market capitalization of $329.3 million that reported zero revenue growth year-over-year and no net profit margin, reflecting an operating net loss in its latest annual statement. The company does not pay dividends and lacks meaningful profitability metrics such as a P/E ratio or return on equity, which is typical for early-stage biotech firms still in development phases. As a pre-revenue or early-revenue stage company, Larimar's financial performance is characteristic of businesses focused on research and drug development rather than commercial operations.